Katja Glinšek (Author), Krištof Bozovičar (Author), Tomaž Bratkovič (Author)

Abstract

The Chinese hamster ovary (CHO) cell line is a well-established platform for the production of biopharmaceuticals due to its ability to express complex therapeutic proteins with human-like glycopatterns in high amounts. The advent of CRISPR technology has opened up new avenues for the engineering of CHO cell lines for improved protein production and enhanced product quality. This review summarizes recent advances in the application of CRISPR technology for CHO cell line engineering with a particular focus on glycosylation modulation, productivity enhancement, tackling adventitious agents, elimination of problematic host cell proteins, development of antibiotic-free selection systems, site-specific transgene integration, and CRISPR-mediated gene activation and repression. The review highlights the potential of CRISPR technology in CHO cell line genome editing and epigenetic engineering for the more efficient and cost-effective development of biopharmaceuticals while ensuring the safety and quality of the final product.

Keywords

Chinese hamster ovary cells;cell line development;CRISPR-Cas;genome editing;glycoengineering;augmenting productivity;

Data

Language: English
Year of publishing:
Typology: 1.02 - Review Article
Organization: UL FFA - Faculty of Pharmacy
UDC: 575.111
COBISS: 150745347 Link will open in a new window
ISSN: 1422-0067
Views: 35
Downloads: 5
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: Slovenian
Secondary keywords: jajčne celice kitajskega hrčka;razvoj celične linije;urejanje genoma;glikoinženiring;enocelično zaporedje;povečanje produktivnosti;Genomika;
Type (COBISS): Article
Pages: 26 str.
Volume: ǂVol. ǂ24
Issue: ǂiss. ǂ9, ǂart. ǂ8144
Chronology: 2023
DOI: 10.3390/ijms24098144
ID: 22635365